Genetic engineering and weight-loss innovation have become focal points for modern healthcare investors. Choosing between CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) depends on your appetite for risk and your belief in their distinct medical breakthroughs.
CRISPR Therapeutics uses gene-editing technology to address diseases at their genetic source, while Viking focuses on metabolic conditions such as obesity that affect millions globally. Both companies represent high-potential opportunities within the biotechnology ******* e, though they currently sit at very different stages of their respective commercial journeys.
CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company recently achieved a major milestone with the commercial launch of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. It operates under a strategic collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages global manufacturing and commercialization. Customer concentration like this adds a layer of risk to the business, as CRISPR Therapeutics relies on this partner for 60% of its profits and losses.
In FY 2025, revenue was about $3.5 million, representing a decrease of approximately 90% from the prior year. This decline is largely due to the transition from receiving one-time milestone payments to building out long-term commercial revenue streams from its approved products. The company reported a net loss of close to $581.6 million. Investing in biotech stocks requires an understanding of how these companies move from early research to global commercialization.
As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This ratio measures total debt relative to the equity shareholders have in the company, with a lower number indicating less reliance on borrowed money. Free cash flow was negative $345.9 million, representing the amount of cash a company generates after paying for capital expenditures.
CRISPR Therapeutics uses gene-editing technology to address diseases at their genetic source, while Viking focuses on metabolic conditions such as obesity that affect millions globally. Both companies represent high-potential opportunities within the biotechnology ******* e, though they currently sit at very different stages of their respective commercial journeys.
CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company recently achieved a major milestone with the commercial launch of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. It operates under a strategic collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages global manufacturing and commercialization. Customer concentration like this adds a layer of risk to the business, as CRISPR Therapeutics relies on this partner for 60% of its profits and losses.
In FY 2025, revenue was about $3.5 million, representing a decrease of approximately 90% from the prior year. This decline is largely due to the transition from receiving one-time milestone payments to building out long-term commercial revenue streams from its approved products. The company reported a net loss of close to $581.6 million. Investing in biotech stocks requires an understanding of how these companies move from early research to global commercialization.
As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This ratio measures total debt relative to the equity shareholders have in the company, with a lower number indicating less reliance on borrowed money. Free cash flow was negative $345.9 million, representing the amount of cash a company generates after paying for capital expenditures.
2 months ago
